Molecular mechanisms involved in hepatic steatosis and insulin resistance

Journal of Diabetes Investigation

Volumn 2, Issue 3, 2011, Pages 170-175

  Matsuzaka, Takashi ^a   Shimano, Hitoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Diabetes; Fatty acids; Liver

Indexed keywords

ACETYLSALICYLIC ACID; GLUCOSE; GLYCEROLIPID; I KAPPA B KINASE BETA; INSULIN; INTERLEUKIN 1BETA; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID COMPOSITION; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN SECRETION; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSCRIPTION REGULATION;

EID: 79961089650     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00111.x     Document Type: Short Survey

References (40)

1. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008; 263: 336-352.
2. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87: 507-520.
3. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-348.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
5. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838
6. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res2009; 50: S74-S79.
7. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229.
8. Mittendorfer B, Magkos F, Fabbrini E, et al. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring) 2009; 17: 1872-1877.
9. Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007; 56: 2759-2765.
10. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1281-G1287.
11. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351.
12. Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS J 2009; 276: 616-621.
13. Shimano H, Horton JD, Shimomura I, et al. Isoform 1c of sterol regulatory element-binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997; 99: 846-854.
14. Yahagi N, Shimano H, Hasty AH, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002; 277: 19353-19357.
15. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem1999; 274: 30028-30032.
16. Ide T, Shimano H, Yahagi N, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 2004; 6: 351-357.
17. Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002; 277: 34182-34190.
18. Chen G, Liang G, Ou J, et al. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 2004; 101: 11245-11250.
19. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature 2007; 445: 219-223.
20. Uyeda K, Repa JJ. Carbohydrate response element-binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006; 4: 107-110.
21. Iizuka K, Bruick RK, Liang G, et al. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 2004; 101: 7281-7286.
22. Iizuka K, Miller B, Uyeda K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab 2006; 291: E358-E364.
23. Monetti M, Levin MC, Watt MJ, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007; 6: 69-78.
24. Minehira K, Young SG, Villanueva CJ, et al. Blocking VLDL secretion causes hepatic steatosisbutdoesnotaffectperipheral lipid stores or insulin sensitivity in mice. J Lipid Res2008; 49: 2038-2044.
25. GrefhorstA,HoekstraJ,DerksTG,et al. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am J Physiol Gastrointest Liver Physiol 2005; 289: G592-G598.
26. Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 2005; 42: 362-371.
27. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003; 100: 3077-3082.
28. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287.
29. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353.
30. Neschen S, Morino K, Hammond LE, et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab 2005; 2: 55-65.
31. Nagle CA, An J, Shiota M, et al. Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J Biol Chem 2007; 282: 14807-14815.
32. McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003; 100: 131-136.
33. Wang X, Devaiah SP, Zhang W, et al. Signaling functions of phosphatidic acid. Prog Lipid Res 2006; 45: 250-278.
34. Matsuzaka T, Shimano H, Yahagi N, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007; 13: 1193-1202.
35. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
36. Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-9054.
37. CaiD,YuanM,FrantzDF,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190.
38. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677.
39. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
40. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27: S49-S52.